KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medpace Holdings (MEDP) EBITDA Margin: 2015-2025

Historic EBITDA Margin for Medpace Holdings (MEDP) over the last 10 years, with Sep 2025 value amounting to 22.52%.

  • Medpace Holdings' EBITDA Margin rose 13.00% to 22.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.66%, marking a year-over-year increase of 161.00%. This contributed to the annual value of 22.51% for FY2024, which is 337.00% up from last year.
  • According to the latest figures from Q3 2025, Medpace Holdings' EBITDA Margin is 22.52%, which was up 2.08% from 22.06% recorded in Q2 2025.
  • Medpace Holdings' 5-year EBITDA Margin high stood at 24.70% for Q4 2024, and its period low was 16.67% during Q2 2021.
  • For the 3-year period, Medpace Holdings' EBITDA Margin averaged around 21.17%, with its median value being 21.52% (2025).
  • As far as peak fluctuations go, Medpace Holdings' EBITDA Margin slumped by 342bps in 2021, and later skyrocketed by 589bps in 2024.
  • Quarterly analysis of 5 years shows Medpace Holdings' EBITDA Margin stood at 19.13% in 2021, then spiked by 155bps to 20.68% in 2022, then crashed by 187bps to 18.81% in 2023, then spiked by 589bps to 24.70% in 2024, then climbed by 13bps to 22.52% in 2025.
  • Its last three reported values are 22.52% in Q3 2025, 22.06% for Q2 2025, and 21.52% during Q1 2025.